Neximmune, INC 10-Q quarterly reports

Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.

OTC.Pink

7 Aug 2024

NEXI

10-Q: NexImmune Reports Q2 2024 Results Amid Strategic Shift and Going Concern Uncertainty

NexImmune reports a net loss of $2.3 million for Q2 2024 as it focuses on its AIM INJ platform and explores strategic alternatives amid substantial doubt about its ability to continue as a going concern.

OTC.Pink

20 May 2024

NEXI

Neximmune, INC

10-Q: NexImmune Reports Q1 2024 Financial Results, Cites Going Concern Uncertainty

NexImmune's Q1 2024 report reveals reduced operating expenses but raises concerns about its ability to continue as a going concern due to recurring losses and limited cash reserves.